A European leader in the secure extraction of imaging and clinical data to accelerate medical research, Medexprim joins the European Commission’s European Federation for Cancer Images project. EUCAIM, a trailblazing federated infrastructure deployment project, aims to create an easy access to cancer images for clinicians, researchers, and innovators to streamline cancer diagnosis, treatment, and care.

The infrastructure will be populated by observational studies from hospitals (21 clinical sites in 12 EU countries), includes clinical images and link with pathology, molecular and laboratory data, and will be expanded with at least 30 additional data providers from 15 countries by the end of the 4-year project. Federated AI solutions will be trained at the hospital data warehouses, keeping data privacy and meeting GDPR requirements.

In this first-of-its-kind European ‘pan-cancer’ infrastructure, Medexprim will contribute to:

• Facilitate the engagement of the data partners in the project, under the leadership of Fundacion para
  la Investigacion del Hospital Universitario La Fe (Hulafe) and Deutsches Krebsforschungszentrum
  (DKFZ) and develop a structured help platform.
• Define the image related data, including clinical data, and metadata that are to be collected from
  each data provider and ensure data quality and data cleaning under the leadership of Foundation for
  Research and Technology Hellas (Forth) and Matical.
• Implement a Central Hub dedicated to hosting an Atlas of Cancer Images, under the leadership of
  Universitat Politecnica de Valencia and Hulafe.

Nicolas Dubost, Head of Medexprim’s partnerships: “Medexprim is thrilled to participate in a ground-breaking European federated infrastructure building on our involvement in 2 major AI4HI projects. The combined energy, expertise, and experience of this 76 parties-wide consortium will undoubtedly improve early detection and treatment options for cancer patients.”

EUCAIM is the cornerstone of the European Commission-initiated European Cancer Imaging Initiative, a
flagship of Europe’s Beating Cancer Plan (EBCP), which aims to foster innovation and deployment of digital technologies in cancer treatment and care, to achieve more precise and faster clinical decision-making, diagnostics, treatments and predictive medicine for cancer patients.

Addressing the fragmentation of existing cancer image repositories, the project builds on repositories from the AI4HI initiative, which consists of 5 large EU-funded projects on big data and Artificial Intelligence in cancer imaging, including clinical images, pathology, molecular and laboratory data: Primage, ChAImeleon (both in which Medexprim is currently involved), EuCanImage, ProCancer-I, and Incisive.

More information on EUCAIM
European Commission Factsheet European Cancer Imaging Initiative and EUCAIM

Medexprim
REAL-WORLD EVIDENCE FOR BETTER CARE
Medexprim is the European leader in secure imaging and clinical data extraction to accelerate medical research. As a Real-World data specialist, Medexprim builds bridges between European academic hospitals, and pharmaceutical, AI and medical device companies. In compliance with the GDPR, Medexprim helps hospitals boost their clinical research strategy and valorize their data, through a suite of software and services designed with and for clinicians. Medexprim provides its partners with secure access to complex, regulatory-grade, multi-omics and multicentric datasets to serve oncology, neurology and cardiology, and help solve the “one patient, one disease, one treatment” equation to accelerate personalized medicine.

Medexprim Linkedin
Press contact: Anne-Sophie Labeta – aslabeta@medexprim.com